FX-322 in Adults With Stable Sensorineural Hearing Loss
Status:
Completed
Trial end date:
2020-12-17
Target enrollment:
Participant gender:
Summary
This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322
compared to placebo in healthy male and female adults with stable sensorineural hearing loss.